Shanghai Medicilon Biomedical Co., Ltd, a leading biopharmaceutical company based in China, has entered into a strategic partnership with Jiangsu Hengrui Medicine Co., Ltd (SHA: 600276), a prominent player in the global pharmaceutical industry. This collaboration aims to leverage Medicilon’s pre-clinical research and development expertise with Hengrui’s innovative drive and market presence to advance the evaluation of novel molecule drugs, including antibody drug conjugates (ADCs), siRNA, and cell and gene therapies (CGTs).
Under the partnership, Medicilon will offer Hengrui a comprehensive suite of preclinical services, encompassing drug efficacy, pharmacokinetics, toxicology, and other critical areas of research and development. This alliance is designed to foster innovation in the biopharmaceutical sector by combining Medicilon’s scientific prowess with Hengrui’s international reputation as a trailblazer in the pharmaceutical industry. While the financial details of the agreement were not disclosed, the partnership signifies a significant step forward in the pursuit of groundbreaking therapies.- Flcube.com
